Format

Send to

Choose Destination
See comment in PubMed Commons below
Front Oncol. 2014 Feb 11;4:16. doi: 10.3389/fonc.2014.00016. eCollection 2014.

Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody.

Author information

1
Department of Physiology and Neurobiology, Geisel Medical School at Dartmouth , Lebanon, NH , USA ; Woomera Therapeutics Inc. , Lebanon, NH , USA.
2
Department of Mathematics and Statistics, The University of Vermont , Burlington, VT , USA.
3
Department of Physiology and Neurobiology, Geisel Medical School at Dartmouth , Lebanon, NH , USA.
4
Woomera Therapeutics Inc. , Lebanon, NH , USA.

Abstract

Previously we demonstrated that human small-cell lung cancer (SCLC) seems to universally express the vasopressin gene, and this leads to the presence of a cell surface marker representing the entire pro-hormone precursor. In this study, we show this marker can be targeted with MAG-1, a mouse monoclonal antibody against a C-terminal moiety on pro-vasopressin. In vitro targeting of cell lines derived from primary and recurrent disease demonstrates attachment of antibody to the cell surface followed by internalization. In vivo targeting with (99)Tc-labeled Fab fragments of MAG-1 shows selective attachment to xenografts. In vivo treatment of tumors from classical cell line, NCI H345, with either ~1.65 mCi (~1.65 mg)/kg body weight (BW) of (90)Yttrium-labeled MAG-1, or ~1.65 mg/kg BW native MAG-1, delivered every second day for 6 days produced similar reductions in the growth rate to ~50% (p < 0.03). When dosing with native MAG-1 was escalated to daily amounts of ~3.3 mg/kg BW over 16 days, tumor growth rates fell to ~33% of saline controls (p < 0.005). Examination of tumors treated with this higher dosing demonstrated the presence in several of extensive apoptosis. Normal tissues seemed to be unaffected. A larger dosage of MAG-1 (~6.6 mg/kg BW) given daily for 14 days was used to treat xenografts of the variant cell line NCI H82 representing recurrent disease. This treatment decreased the rate of increase in tumor size by half, and doubling time ~3-fold. Increases in cleaved PARP supported increased apoptosis with antibody treatment. We believe these data provide evidence that the growth rate of SCLC tumors can be extensively reduced by treatment with MAG-1 antibody, and that a humanized form of this antibody could, in future, be potentially used for targeting therapy onto recurrent SCLC in patients.

KEYWORDS:

GRSA surface marker; MAG-1 antibody; STEPS concept; pro-vasopressin; recurrent disease; small-cell lung cancer; targeted treatment

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Support Center